

Min Hee Hong

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/8851689/min-hee-hong-publications-by-year.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

78
papers

1,280
citations

20
h-index

34
g-index

89
ext. papers

1,860
ext. citations

5.3
avg, IF

4.58
L-index

#	Paper	IF	Citations
78	Predicting treatment outcomes using F-FDG PET biomarkers in patients with non-small-cell lung cancer receiving chemoimmunotherapy.. <i>Therapeutic Advances in Medical Oncology</i> , 2022 , 14, 175883592110681732	5.4	10681732
77	Lymphocyte dynamics during and after chemo-radiation correlate to dose and outcome in stage III NSCLC patients undergoing maintenance immunotherapy.. <i>Radiotherapy and Oncology</i> , 2022 ,	5.3	4
76	Primary Tumor Suppression and Systemic Immune Activation of Macrophages through the Sting Pathway in Metastatic Skin Tumor.. <i>Yonsei Medical Journal</i> , 2022 , 63, 42-55	3	1
75	Molecular landscape of osimertinib resistance in patients and patient-derived preclinical models.. <i>Therapeutic Advances in Medical Oncology</i> , 2022 , 14, 17588359221079125	5.4	0
74	Disproportional enrichment of FoxP3 CD4 regulatory T cells shapes a suppressive tumour microenvironment in head and neck squamous cell carcinoma.. <i>Clinical and Translational Medicine</i> , 2022 , 12, e753	5.7	1
73	The Development of AXL Inhibitors in Lung Cancer: Recent Progress and Challenges.. <i>Frontiers in Oncology</i> , 2022 , 12, 811247	5.3	3
72	Incorporation of SKI-G-801, a Novel AXL Inhibitor, With Anti-PD-1 Plus Chemotherapy Improves Anti-Tumor Activity and Survival by Enhancing T Cell Immunity.. <i>Frontiers in Oncology</i> , 2022 , 12, 821391	5.3	0
71	SKI-G-801, an AXL kinase inhibitor, blocks metastasis through inducing anti-tumor immune responses and potentiates anti-PD-1 therapy in mouse cancer models.. <i>Clinical and Translational Immunology</i> , 2022 , 11, e1364	6.8	2
70	A Phase 1/2 Study of Lazertinib 240 mg in Patients with Advanced EGFR T790M-Positive Non-Small Cell Lung Cancer After Prior EGFR Tyrosine Kinase Inhibitors.. <i>Journal of Thoracic Oncology</i> , 2021 ,	8.9	4
69	Overexpression of PVR and PD-L1 and its association with prognosis in surgically resected squamous cell lung carcinoma. <i>Scientific Reports</i> , 2021 , 11, 8551	4.9	2
68	Intracranial failure after hippocampal-avoidance prophylactic cranial irradiation in limited-stage small-cell lung cancer patients. <i>Scientific Reports</i> , 2021 , 11, 7435	4.9	1
67	Genetic Analysis and Operative Outcomes in Patients with Oncogene-Driven Advanced NSCLC Treated with Cytoreductive Surgery as a Component of Local Consolidative Therapy. <i>Cancers</i> , 2021 , 13,	6.6	2
66	Distinct Characteristics and Clinical Outcomes to Predict the Emergence of Amplification in Patients with Non-Small Cell Lung Cancer Who Developed Resistance after Treatment with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors. <i>Cancers</i> , 2021 , 13,	6.6	3
65	Analyses of CNS Response to Osimertinib in Patients with T790M-Positive Advanced NSCLC from ASTRIS Korean Subset, Open-Label Real-World Study. <i>Cancers</i> , 2021 , 13,	6.6	1
64	Dynamic changes in circulating PD-1CD8 T lymphocytes for predicting treatment response to PD-1 blockade in patients with non-small-cell lung cancer. <i>European Journal of Cancer</i> , 2021 , 143, 113-126	7.5	9
63	Blocking TIM-3 in Treatment-refractory Advanced Solid Tumors: A Phase Ia/b Study of LY3321367 with or without an Anti-PD-L1 Antibody. <i>Clinical Cancer Research</i> , 2021 , 27, 2168-2178	12.9	22
62	Treatment Patterns and Clinical Outcomes in Korean Cancer Patients With Venous Thromboembolism: A Retrospective Cohort Study. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2021 , 27, 1076029620979575	3.3	0

61	Overexpression of poliovirus receptor is associated with poor prognosis in head and neck squamous cell carcinoma patients. <i>Journal of Cancer Research and Clinical Oncology</i> , 2021 , 147, 2741-2750	4.9	0
60	Real-world outcomes of anti-PD1 antibodies in platinum-refractory, PD-L1-positive recurrent and/or metastatic non-small cell lung cancer, and its potential practical predictors: first report from Korean Cancer Study Group LU19-05. <i>Journal of Cancer Research and Clinical Oncology</i> , 2021 , 147, 2459-2469	4.9	1
59	Abstract 1106: BRAF and EGFR fusion as a novel mechanism of resistance mechanism to Lazertinib, 3rd- generation EGFR-TKI, in EGFR-mutant NSCLC 2021 ,		2
58	Clinical decision support algorithm based on machine learning to assess the clinical response to anti-programmed death-1 therapy in patients with non-small-cell lung cancer. <i>European Journal of Cancer</i> , 2021 , 153, 179-189	7.5	5
57	A phase II study of poziotinib in patients with recurrent and/or metastatic head and neck squamous cell carcinoma. <i>Cancer Medicine</i> , 2021 , 10, 7012-7020	4.8	2
56	Nephrotoxicity of cancer therapeutic drugs: Focusing on novel agents. <i>Kidney Research and Clinical Practice</i> , 2021 , 40, 344-354	3.6	2
55	Efficacy and safety of atezolizumab, in combination with etoposide and carboplatin regimen, in the first-line treatment of extensive-stage small-cell lung cancer: a single-center experience. <i>Cancer Immunology, Immunotherapy</i> , 2021 , 1	7.4	0
54	The feasibility and safety of radical esophagectomy in patients receiving neoadjuvant chemoradiotherapy with pembrolizumab for esophageal squamous cell carcinoma. <i>Journal of Thoracic Disease</i> , 2020 , 12, 6426-6434	2.6	6
53	Antitumor Activity of Amivantamab (JNJ-61186372), an EGFR-MET Bispecific Antibody, in Diverse Models of Exon 20 Insertion-Driven NSCLC. <i>Cancer Discovery</i> , 2020 , 10, 1194-1209	24.4	68
52	Peripheral natural killer cells and myeloid-derived suppressor cells correlate with anti-PD-1 responses in non-small cell lung cancer. <i>Scientific Reports</i> , 2020 , 10, 9050	4.9	16
51	Molecular subtypes of oropharyngeal cancer show distinct immune microenvironment related with immune checkpoint blockade response. <i>British Journal of Cancer</i> , 2020 , 122, 1649-1660	8.7	8
50	Immunotherapy for Non-small Cell Lung Cancer: Current Landscape and Future Perspectives. <i>Immune Network</i> , 2020 , 20, e10	6.1	51
49	Phase 2 study of afatinib among patients with recurrent and/or metastatic esophageal squamous cell carcinoma. <i>Cancer</i> , 2020 , 126, 4521-4531	6.4	3
48	Comprehensive analyses of immunodynamics and immunoreactivity in response to treatment in -positive non-small-cell lung cancer 2020 , 8,		7
47	Mouse-human co-clinical trials demonstrate superior anti-tumour effects of buparlisib (BKM120) and cetuximab combination in squamous cell carcinoma of head and neck. <i>British Journal of Cancer</i> , 2020 , 123, 1720-1729	8.7	8
46	Genome-wide identification of differentially methylated promoters and enhancers associated with response to anti-PD-1 therapy in non-small cell lung cancer. <i>Experimental and Molecular Medicine</i> , 2020 , 52, 1550-1563	12.8	22
45	Recurrent Sympathetic Ophthalmia with Annular Choroidal Detachment after Pembrolizumab Treatment: A Case Report. <i>Ocular Immunology and Inflammation</i> , 2020 , 28, 864-867	2.8	5
44	Establishment and characterization of patient-derived xenografts as preclinical models for head and neck cancer. <i>BMC Cancer</i> , 2020 , 20, 316	4.8	7

43	Repotrectinib Exhibits Potent Antitumor Activity in Treatment-Naïve and Solvent-Front-Mutant ROS1-Rearranged Non-Small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2020 , 26, 3287-3295	12.9	26
42	Impact of Treatment-Related Lymphopenia on Immunotherapy for Advanced Non-Small Cell Lung Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2019 , 105, 1065-1073	4	41
41	YH25448, an Irreversible EGFR-TKI with Potent Intracranial Activity in EGFR Mutant Non-Small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2019 , 25, 2575-2587	12.9	33
40	Real-World Analysis of the Efficacy of Rebiopsy and Mutation Test of Tissue and Plasma Samples in Drug-Resistant Non-Small Cell Lung Cancer. <i>Yonsei Medical Journal</i> , 2019 , 60, 525-534	3	15
39	A phase Ib study of the combination of afatinib and ruxolitinib in EGFR mutant NSCLC with progression on EGFR-TKIs. <i>Lung Cancer</i> , 2019 , 134, 46-51	5.9	16
38	Neoadjuvant therapy for thymic neoplasms reduces tumor volume per 3D-reconstructed images but does not improve the complete resection rate. <i>PLoS ONE</i> , 2019 , 14, e0214291	3.7	1
37	Comprehensive analysis of the characteristics and treatment outcomes of patients with non-small cell lung cancer treated with anti-PD-1 therapy in real-world practice. <i>Journal of Cancer Research and Clinical Oncology</i> , 2019 , 145, 1613-1623	4.9	40
36	Indoor radon exposure increases tumor mutation burden in never-smoker patients with lung adenocarcinoma. <i>Lung Cancer</i> , 2019 , 131, 139-146	5.9	13
35	Hyperprogressive disease during PD-1/PD-L1 blockade in patients with non-small-cell lung cancer. <i>Annals of Oncology</i> , 2019 , 30, 1104-1113	10.3	120
34	Dynamic changes in PD-L1 expression and CD8 T cell infiltration in non-small cell lung cancer following chemoradiation therapy. <i>Lung Cancer</i> , 2019 , 136, 30-36	5.9	13
33	Predictive factors for the development of diabetes in cancer patients treated with phosphatidylinositol 3-kinase inhibitors. <i>Cancer Chemotherapy and Pharmacology</i> , 2019 , 84, 405-414	3.5	5
32	Lazertinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: results from the dose escalation and dose expansion parts of a first-in-human, open-label, multicentre, phase 1-2 study. <i>Lancet Oncology</i> , 2019 , 20, 1681-1690	21.7	47
31	Targeting YAP to overcome acquired resistance to ALK inhibitors in ALK-rearranged lung cancer. <i>EMBO Molecular Medicine</i> , 2019 , 11, e10581	12	21
30	A phase II trial of preoperative chemoradiotherapy and pembrolizumab for locally advanced esophageal squamous cell carcinoma (ESCC).. <i>Journal of Clinical Oncology</i> , 2019 , 37, 4027-4027	2.2	11
29	Patient-Derived Cells to Guide Targeted Therapy for Advanced Lung Adenocarcinoma. <i>Scientific Reports</i> , 2019 , 9, 19909	4.9	6
28	Molecular characterization of lung adenocarcinoma from Korean patients using next generation sequencing. <i>PLoS ONE</i> , 2019 , 14, e0224379	3.7	9
27	High CD3 and ICOS and low TIM-3 expression predict favourable survival in resected oesophageal squamous cell carcinoma. <i>Scientific Reports</i> , 2019 , 9, 20197	4.9	9
26	Incidence, in-hospital mortality, and readmission among patients with alcoholic hepatitis in Korea: A nationwide study. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2019 , 34, 747-754	4	5

25	Enhancer Remodeling and MicroRNA Alterations Are Associated with Acquired Resistance to ALK Inhibitors. <i>Cancer Research</i> , 2018 , 78, 3350-3362	10.1	23
24	Clinical characteristics of T790M-positive lung adenocarcinoma after resistance to epidermal growth factor receptor-tyrosine kinase inhibitors with an emphasis on brain metastasis and survival. <i>Lung Cancer</i> , 2018 , 121, 12-17	5.9	15
23	Efficacy and safety of vinorelbine plus cisplatin chemotherapy for patients with recurrent and/or metastatic salivary gland cancer of the head and neck. <i>Head and Neck</i> , 2018 , 40, 55-62	4.2	11
22	ERK-dependent IL-6 autocrine signaling mediates adaptive resistance to pan-PI3K inhibitor BKM120 in head and neck squamous cell carcinoma. <i>Oncogene</i> , 2018 , 37, 377-388	9.2	20
21	Characteristics and Outcome of ROS1-Positive Non-Small Cell Lung Cancer Patients in Routine Clinical Practice. <i>Journal of Thoracic Oncology</i> , 2018 , 13, 1373-1382	8.9	57
20	Establishment of a platform of non-small-cell lung cancer patient-derived xenografts with clinical and genomic annotation. <i>Lung Cancer</i> , 2018 , 124, 168-178	5.9	15
19	YH25448, a 3rd generation EGFR-TKI, in patients with EGFR-TKI-resistant NSCLC: Phase I/II study results.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 9033-9033	2.2	2
18	Co-clinical trials demonstrate predictive biomarkers for dicitinib, an FGFR inhibitor, in lung squamous cell carcinoma. <i>Annals of Oncology</i> , 2017 , 28, 1250-1259	10.3	37
17	P3.02b-119 YH25448, a Highly Selective 3rd Generation EGFR TKI, Exhibits Superior Survival over Osimertinib in Animal Model with Brain Metastases from NSCLC. <i>Journal of Thoracic Oncology</i> , 2017 , 12, S1265-S1266	8.9	7
16	Povidone-iodine for the management of oral mucositis during cancer therapy. <i>Oncology Reviews</i> , 2017 , 11, 341	4.3	5
15	Detection of activating and acquired resistant mutation in plasma from EGFR-mutated NSCLC patients by peptide nucleic acid (PNA) clamping-assisted fluorescence melting curve analysis. <i>Oncotarget</i> , 2017 , 8, 65111-65122	3.3	17
14	Concordance of programmed death-ligand 1 expression between primary and metastatic non-small cell lung cancer by immunohistochemistry and RNA hybridization. <i>Oncotarget</i> , 2017 , 8, 87234-87243	3.3	14
13	Phase II study of afatinib in recurrent and/or metastatic esophageal squamous cell carcinoma (R/M ESCC) (KCSG HN14-18).. <i>Journal of Clinical Oncology</i> , 2017 , 35, 4051-4051	2.2	
12	PD-L1 expression on immune cells, but not on tumor cells, is a favorable prognostic factor for head and neck cancer patients. <i>Scientific Reports</i> , 2016 , 6, 36956	4.9	154
11	Phase II gemcitabine and capecitabine combination therapy in recurrent or metastatic breast cancer patients pretreated with anthracycline and taxane. <i>Cancer Chemotherapy and Pharmacology</i> , 2014 , 74, 799-808	3.5	6
10	Synthesize of Mesoporous ZnO Thin Films and Gas Sensing Property. <i>Advanced Materials Research</i> , 2014 , 960-961, 157-160	0.5	
9	MAPK-signaling inhibition as a genome-based precision medicine in refractory osteosarcoma.. <i>Journal of Clinical Oncology</i> , 2014 , 32, e22164-e22164	2.2	
8	Everolimus-associated pneumonitis in Asian metastatic renal cell carcinoma patients.. <i>Journal of Clinical Oncology</i> , 2014 , 32, e15596-e15596	2.2	

7	Mesoporous Thin Films: Thermoelectric Application. <i>Applied Mechanics and Materials</i> , 2012 , 260-261, 34-39	0.3	1
6	Sunitinib for Asian patients with advanced renal cell carcinoma: a comparable efficacy with different toxicity profiles. <i>Oncology</i> , 2011 , 80, 395-405	3.6	45
5	Outcomes of multiple salvage chemotherapy for advanced gastric cancer: implications for clinical practice and trial design. <i>Cancer Chemotherapy and Pharmacology</i> , 2010 , 66, 797-805	3.5	20
4	Treatment outcomes of sunitinib treatment in advanced renal cell carcinoma patients: a single cancer center experience in Korea. <i>Cancer Research and Treatment</i> , 2009 , 41, 67-72	5.2	57
3	Prognosis of pN3 stage gastric cancer. <i>Cancer Research and Treatment</i> , 2009 , 41, 73-9	5.2	16
2	Clinical value of ezrin expression in primary osteosarcoma. <i>Cancer Research and Treatment</i> , 2009 , 41, 138-44	5.2	33
1	Docetaxel versus paclitaxel combined with 5-FU and leucovorin in advanced gastric cancer: combined analysis of two phase II trials. <i>Cancer Research and Treatment</i> , 2009 , 41, 196-204	5.2	21